prikaz prve stranice dokumenta Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
  Download
PDF 2.44 MB
Professional paper - Professional paper
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
Pharmacological Research, 166 (2021); 105499. https://doi.org/10.1016/j.phrs.2021.105499
Banach, Maciej; Penson, Peter E.; Vrablik, Michal; Bunc, Matjaz; Dyrbus, Krzysztof; Fedacko, Jan; Gaita, Dan; Gierlotka, Marek; Jarai, Zoltan; Magda, Stefania Lucia; Margetić, Eduard; Margoczy, Roman; Durak-Nalbantic, Azra; Ostadal, Petr; Pella, Daniel; Trbušić, Matias; Udroiu, Cristian Alexandru; Vlachopoulos, Charalambos; Vulic, Dusko; Fras, Zlatko; Dudek, Dariusz; Reiner, Željko More authors...

Cite this document

Banach, M., Penson, P. E., Vrablik, M., Bunc, M., Dyrbus, K., Fedacko, J. ... Reiner, Ž. (2021). Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research, 166.. doi: 10.1016/j.phrs.2021.105499

Banach, Maciej, et al. "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)." Pharmacological Research, vol. 166, 2021. https://doi.org/10.1016/j.phrs.2021.105499

Banach, Maciej, Peter E. Penson, Michal Vrablik, Matjaz Bunc, Krzysztof Dyrbus, Jan Fedacko, Dan Gaita, et al. "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)." Pharmacological Research 166 (2021). https://doi.org/10.1016/j.phrs.2021.105499

Banach, M., et al. (2021) 'Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)', Pharmacological Research, 166. doi: 10.1016/j.phrs.2021.105499

Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, and sur.. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research [Internet]. 2021 April [cited 2024 October 09];166. doi: 10.1016/j.phrs.2021.105499

M. Banach, et al., "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)", Pharmacological Research, vol. 166, April 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:914316. [Accessed: 09 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
AuthorMaciej Banach
AuthorPeter E. Penson
AuthorMichal Vrablik
AuthorMatjaz Bunc
AuthorKrzysztof Dyrbus
AuthorJan Fedacko
AuthorDan Gaita
AuthorMarek Gierlotka
AuthorZoltan Jarai
AuthorStefania Lucia Magda
AuthorEduard Margetić
AuthorRoman Margoczy
AuthorAzra Durak-Nalbantic
AuthorPetr Ostadal
AuthorDaniel Pella
AuthorMatias Trbušić
AuthorCristian Alexandru Udroiu
AuthorCharalambos Vlachopoulos
AuthorDusko Vulic
AuthorZlatko Fras
AuthorDariusz Dudek
AuthorŽeljko Reiner
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low density lipoprotein cholesterol (LDL-C), "lower is better for longer", and the recent data have strongly emphasized the need of also "the earlier the better". In addition to statins, which have been available for several decades, the availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional very effective approach to LLT, especially for those at very high and extremely high cardiovascular risk. LLT is initiated as a response to an individual's calculated risk of future ASCVD and is intensified over time in order to meet treatment goals. However, in real-life clinical practice goals are not met in a substantial proportion of patients. This Position Paper complements existing guidelines on the management of lipids in patients following ACS. Bearing in mind the very high risk of further events in ACS, we propose practical solutions focusing on immediate combination therapy in strict clinical scenarios, to improve access and adherence to LLT in these patients. We also define an 'Extremely High Risk' group of individuals following ACS, completing the attempt made in the recent European guidelines, and suggest mechanisms to urgently address lipid-medicated cardiovascular risk in these patients.
Keywords (english)
Languageenglish
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titlePharmacological Research
Numberingvol. 166, 105499
p-ISSN1043-6618
e-ISSN1096-1186
DOIhttps://doi.org/10.1016/j.phrs.2021.105499
URN:NBNurn:nbn:hr:105:914316
Publication2021-04
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S1043661821000839
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2021-06-29 07:46:40